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Background: Left ventricular assist devices (LVAD) improve quality of life (QoL); however, up to 20% of LVAD patients (pts) experience persistent 
moderate to severe heart failure symptoms.
Methods: Clinical, laboratory, hemodynamic variables, and previously defined risk scores of right ventricular (RV) function from pts supported for 
at least 6 months in the HeartMate II clinical trials (n=713) were evaluated using logistic regression to identify predictors of improved QoL. QoL 
Responders (Qol-R) were defined as those pts whose: a) Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ) was > 50 points; 
or b) Minnesota Living with Heart Failure Questionnaire (MLHFQ) score was < 52 points (scores below the lowest quartile at 6 months). Pts who did 
not meet these criteria were identified as non-Responders (QoL-NR).
Results: There were 82% pts in the QoL-R and 18% in QoL-NR groups after LVAD. In the QoL-NR group, 68% pts experienced QoL improvement of 
at least 5 points in the KCCQ and 59% in the MLHFQ score. Age, gender, and device strategy (bridge-to-transplant vs. destination therapy) were not 
associated with QOL response. Multivariable correlates of QoL-NR were diabetes mellitus (DM), lower mean pulmonary artery pressure, and HMII RV 
risk score (Table 1).
Conclusions: Pre-operative RV dysfunction and DM are predictive of lower QoL following LVAD therapy and should be considered as risk factors for 
reduced QoL improvement during the pt selection process.
Risk Factors for Lower Quality of Life after LVAD
Risk Factor Univariate Odds Ratio [5%-95%] p-value Multivariate Odds Ratio [5%-95%] p-value
Diabetes 1.56 [1.04-2.33] 0.03 1.82[1.20-2.78] 0.005
HMII RV Risk Score 1.75 [1.02-3.03] 0.042 1.75 [1.00-3.13] 0.050
Mean Pulmonary Artery Pressure (per 1 mmHg 
increase)
0.98 [0.95-1.00] 0.022 0.97 [0.95-0.99] 0.010
Body Surface Area (per 1 m2 increase) 2.27 [1.10-4.55] 0.027 NS
